Avacta: AVA6103 (FAP-Exd) starts Phase Ia FOCUS clinical trial
Avacta has treated its first patient in the first clinical trial of FAP-Exd (AVA6103), a second-generation pre|CISION-enabled peptide-drug conjugate (PDC). FAP-Exd is a novel sustained release PDC with an exatecan payload intended to address the known limitations of the potent Topo I inhibitors (short half-life, severe systemic toxicities). The FOCUS study is designed to generate robust data in four specifically selected solid tumours (cervical, gastric, pancreatic, and small cell lung cancer). The results, from c 144 patients, will determine the FAP release kinetics, examine safety, and provide preliminary efficacy of FAP-Exd. Phase Ia results should be available in late-2026, with Phase Ib expected to start in early-2027. These data will help validate the clinical utility, commercial potential, and inherent value of the FAP-activated PDC pre|CISION platform. Our updated valuation is £471m/$603m, or 103p/share.Avacta Group is a biotechnology company that is developing biotherapeutics and reagents based on its proprietary Affimer technology, an engineered alternative to antibodies. Affimer® reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a range of applications where antibodies and aptamers have limitations. Co. has two operating segments: Life Sciences, which provides custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development; and Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.